Discounted Cash Flow
Gyre Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-16.9m | $-18.9m | — | $-21.75 |
| 2017 | $1.0m | $-21.6m (-27.2%) | $-20.0m (-5.4%) | -2118.0% | — |
| 2018 | $6.0k (-99.4%) | $-30.1m (-39.4%) | $-28.9m (-44.9%) | -500916.7% (-23550.7%) | — |
| 2019 | — | $-55.2m (-83.6%) | $-43.7m (-51.0%) | — | — |
| 2020 | $20.9m | $-56.2m (-1.9%) | $-55.3m (-26.6%) | -268.5% | — |
| 2021 | $7.3m (-65.0%) | $-87.9m (-56.4%) | $-84.6m (-52.9%) | -1198.3% (-346.3%) | — |
| 2022 | $794.0k (-89.2%) | $-8.2m (90.6%) | $-33.8m (60.0%) | -1038.0% (13.4%) | $-0.26 |
| 2023 | $113.5m (14188.4%) | $-85.5m (-937.1%) | $17.4m (151.4%) | -75.3% (92.7%) | $-1.41 (-442.3%) |
| 2024 | $105.8m (-6.8%) | $17.9m (120.9%) | $-6.0m (-134.3%) | 16.9% (122.5%) | $0.14 (109.9%) |
| 2025 | $116.6m (10.2%) | $9.9m (-44.8%) | $-180.0k (97.0%) | 8.5% (-49.9%) | $0.06 (-57.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.